Semaglutide vs Liraglutide: Wegovy/Ozempic vs Saxenda/Victoza Compared

Semaglutide and liraglutide are both GLP-1 receptor agonists, but they belong to different eras of obesity medicine.

Liraglutide came first. It is sold as Saxenda for weight management and Victoza for type 2 diabetes. Semaglutide came later, with weekly injectable products such as Wegovy and Ozempic. For most weight-loss searches, semaglutide is the stronger and more convenient option.

For broader approved-drug rankings, read best GLP-1 for weight loss.

Quick Comparison

Question	Semaglutide	Liraglutide
Drug class	GLP-1 receptor agonist	GLP-1 receptor agonist
Major brands	Wegovy, Ozempic, Rybelsus	Saxenda, Victoza
Typical injection frequency	Weekly for Wegovy/Ozempic injections	Daily for Saxenda/Victoza
Weight-loss edge	Stronger average weight loss in direct obesity comparison	Lower average weight loss, older track record
Best practical use	Most people comparing modern GLP-1 weight-loss options	When access, supply, cost or tolerability favors it

Why Semaglutide Usually Wins

The direct STEP 8 comparison found a large gap between semaglutide and liraglutide in adults with overweight or obesity. Semaglutide produced much larger average weight loss and is weekly, which also helps adherence for many people.

Evidence point	Semaglutide	Liraglutide	Meaning
Direct STEP 8 obesity trial	About 15.8% average body-weight reduction	About 6.4% average body-weight reduction	Semaglutide had the clear weight-loss advantage.
Dosing rhythm	Weekly injection for major injectable brands	Daily injection	Weekly is easier for many patients.
Half-life pattern	Long-acting	Shorter-acting	This is one reason dosing schedules differ.

When Liraglutide Can Still Make Sense

Liraglutide is not obsolete just because semaglutide is stronger on average. It can still be relevant when:

• Insurance coverage favors Saxenda or Victoza.
• Newer weekly drugs are unavailable.
• A clinician wants an older daily option with a longer clinical history.
• A patient prefers the ability to stop a shorter-acting daily drug quickly if side effects are a problem.

That said, for weight loss alone, the average efficacy gap is hard to ignore.

Side Effects

Both drugs share GLP-1 class effects:

• Nausea.
• Vomiting.
• Diarrhea.
• Constipation.
• Reflux or abdominal discomfort.
• Reduced appetite.
• Injection-site reactions.

Serious warnings and contraindications come from each label. Do not assume that a lower average weight-loss drug is automatically safer. The right comparison is individual tolerability plus label risks.

Bottom Line

Semaglutide is usually the better weight-loss comparison because it is stronger on average and easier to take as a weekly injectable. Liraglutide remains a valid older GLP-1 option when access, coverage or clinician judgment points that way.

For the next comparison up, read semaglutide vs tirzepatide.

FAQ

Is semaglutide better than liraglutide for weight loss?

In direct obesity-trial data, semaglutide produced substantially more average weight loss than liraglutide.

Is Saxenda the same as Wegovy?

No. Saxenda is liraglutide, a daily GLP-1 injection. Wegovy is semaglutide, a longer-acting GLP-1 product used for weight management.

Why is liraglutide daily while semaglutide is weekly?

Semaglutide has a much longer half-life than liraglutide, which supports weekly dosing for injectable semaglutide products.

Does liraglutide still have a role?

Yes. It may matter when coverage, supply, tolerability or clinician preference points away from newer weekly agents.

Are side effects different?

The general GLP-1 side-effect pattern is similar, with gastrointestinal symptoms most common. Dose, titration and individual tolerance matter.

References

1. Rubino DM, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity. JAMA.

2. Novo Nordisk. Wegovy prescribing information.

3. Novo Nordisk. Saxenda prescribing information.

4. Novo Nordisk. Ozempic prescribing information.